FINWIRES · TerminalLIVE
FINWIRES

ウェドブッシュ証券は、タスクアスの株価は魅力的なエントリーポイントを提供していると述べている。

By

-- ウェドブッシュ証券は水曜日の調査レポートで、TaskUs(TASK)の株価は魅力的なエントリーポイントを提供しており、同社は労働分野における人工知能(AI)自動化の拡大を活かす態勢が整っていると述べた。 アナリストらは、AI自動化の専門家との協議を通じて、TaskUsが長年にわたる顧客基盤、業界特化、そしてAIデータラベリングおよびアノテーションへの早期参入といった点で、買収対象として有力視されていることを指摘した。 レポートによると、TaskUsのAIサービスは「目に見える」追い風を受けており、Meta Platforms(META)によるScale AIの買収は、競合他社がTaskUsに事業を移す要因となる可能性が高いという。 ウェドブッシュ証券は、TaskUsのデジタル顧客体験、AIサービス、および安全部門間のシナジー効果が、市場で過小評価されている「より強固な」顧客関係を構築していると指摘した。 同証券は、TaskUs株の投資判断を「アウトパフォーム」に据え置き、目標株価を1株当たり14ドルとした。

Price: $7.25, Change: $+0.47, Percent Change: +6.93%

Related Articles

Asia

Biocytogen Pharmaceuticals Turns to Profit in Q1

Biocytogen Pharmaceuticals (Beijing) (HKG:2315) recorded an attributable profit of 104 million yuan in the first quarter of 2026, compared with an attributable loss of 13.2 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share stood at 0.23 yuan, compared with a loss per share of 0.03 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 74% in the three months to 433.1 million yuan from 249.3 million yuan in the year-ago period, driven by a substantially higher revenue contribution from pharmacology and efficacy services and animal models.The pharmaceutical company attributed the higher profit mainly to revenue growth and improved operating efficiency amid expense management.

$HKG:2315
Oil & Energy

Market Chatter: LNG Carrier Orders Surge as Global Output Defies Iran War Tensions

Global demand for liquefied natural gas carriers is rebounding sharply in 2026, despite the ongoing US-Iran conflict, Reuters reported Monday, citing analysts and industry experts.Analysts report that surging LNG production and a transition toward high-efficiency vessels are fueling the recovery.According to the report, Shipbuilders in South Korea and China have already secured 35 new build contracts in Q1 alone.The resurgence in construction comes despite the escalating US-Iran war, which has choked the Strait of Hormuz and raised fears of a prolonged shipping downturn.However, market experts suggest that the need for modern, fuel-efficient tonnage is outweighing immediate freight rate concerns, it said.These new vessels, which cost between $250 million and $260 million and take over three years to complete, are increasingly necessary as older, steam-propelled tankers are scrapped at record rates to meet stricter global emissions regulations.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Research

Canaccord Genuity Initiates Coverage on Structure Therapeutics With Buy Rating, $101 Price Target

Structure Therapeutics (GPCR) has an average rating of Buy and mean price target of $108.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$GPCR